Facilitating the Safe Integration of Bispecific Antibodies into Community Oncology NEW YORK, Sept. 25, 2024 /PRNewswire/ -- Canopy, the first Continuous…
New investment supports DxA's mission to advance the development of scalable and universally accessible diagnostics.Blood tests will be key to…
WOBURN, MA / ACCESSWIRE / September 25, 2024 / Biofrontera Inc. (NASDAQ:BFRI), a biopharmaceutical company specializing in the commercialization of…
CHICAGO, IL / ACCESSWIRE / September 25, 2024 / Cosmos Health Inc. ("Cosmos Health" or the "Company'') (NASDAQ:COSM), a diversified,…
--Data will be presented at the conference in October in MontrealMarlborough, Massachusetts--(Newsfile Corp. - September 25, 2024) - Phio Pharmaceuticals…
– Through selective inhibition of proinflammatory transcription, p300 KAT inhibition modulates the activity and function of multiple pro-inflammatory signaling pathways…
SAN FRANCISCO, CA / ACCESSWIRE / September 25, 2024 / Jaguar Health, Inc. (NASDAQ:JAGX) today announced that Lisa Conte, the…
Company expands relationship with manufacturing partner Medical Murray, and continues active exploration of standalone opportunities for RenovoCath RenovoCath Image RenovoCath…
ORION CORPORATION PRESS RELEASE 25 SEPTEMBER 2024 at 15.00 EEST Orion and Aitia enter AI-Driven Drug Discovery and Drug Simulation…
Naporafenib is a potential first-in-class and best-in-class pan-RAF inhibitor Erasca is also evaluating naporafenib plus trametinib in the ongoing SEACRAFT-2…